Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SILO PharmaSILO 42 PS Ratio is 30.43 as of Sep. 11, 2026, which is 60% below its 10-year median of 75.66. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 936 Biotechnology companies, SILO Pharma ranks worse than 73.08% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, SILO Pharma's share price is $2.10.
SILO Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.07. Hence, SILO Pharma's PS Ratio for today is 30.43.
Good Sign:
SILO Pharma Inc stock PS Ratio (=30.43) is close to 1-year low of 28.26.
The historical rank and industry rank for SILO Pharma's PS Ratio or its related term are showing as below:
SILO'
s PS Ratio Range Over the Past 10 Years
Min: 11.42 Med: 75.66 Max: 7402.33
Current: 30.44
During the past 13 years, SILO Pharma's highest PS Ratio was 7402.33. The lowest was 11.42. And the median was 75.66.
SILO's PS Ratio is ranked worse than 73.08% of 936
companies
in the Biotechnology industry
Industry Median: 9.495
vs SILO: 30.44
SILO Pharma Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of SILO Pharma was -69.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -35.20% per year.
During the past 13 years, SILO Pharma's highest 3-Year average Revenue per Share Growth Rate was -19.10% per year. The lowest was -35.20% per year. And the median was -29.00% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
SILO Pharma PS Ratio Related Terms
SILO Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for SILO Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SILO Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where SILO Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
SILO Pharma's Share Price of today is $2.10. SILO Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
SILO Pharma (SILO) has a PS Ratio of 30.43 as of Sep. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on SILO Pharma and its competitors. This is 60% below median its historical median of 75.66. Over the past decade, SILO Pharma's PS Ratio has ranged from 11.42 to 7,402.33. According to the industry distribution chart, SILO Pharma ranks #684 out of 936 companies in the Biotechnology industry, placing it in the top 73.1%.
Is SILO Pharma's PS Ratio too high?
SILO Pharma's current PS Ratio of 30.43 is 60% below median its 10-year median of 75.66. Over the past 10 years, this metric has ranged from a low of 11.42 to a high of 7,402.33. The Biotechnology industry median PS Ratio is 9.50. SILO Pharma's value of 30.43 is 220.5% above this industry median. Based on the distribution chart, SILO Pharma ranks #684 out of 936 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's PS Ratio compare to ELAB and GLMD?
According to the Biotechnology industry distribution chart, SILO Pharma ranks #684 out of 936 companies for PS Ratio. This places SILO Pharma in the lower half of its industry. The industry median PS Ratio is 9.50. SILO Pharma's value of 30.43 is 220.5% above this benchmark. Historically, SILO Pharma's own PS Ratio has ranged from 11.42 to 7,402.33 over the past decade. While the company's 10-year median is 75.66 vs. the industry median of 9.50, SILO Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SILO Pharma's current PS Ratio of 30.43 is 220.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on SILO Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SILO Pharma's current PS Ratio is 30.43, which is 60% below median its own 10-year median of 75.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current PS Ratio is 30.43, which is 60% below median its 10-year median of 75.66 and 220.5% above the Biotechnology industry median of 9.50. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For SILO Pharma (SILO), the current PS Ratio is 30.43 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SILO Pharma (SILO) Overvalued in 2026?
Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued.
The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44.
GuruFocus considers SILO Pharma to be Possible Value Trap.
Key valuation signals for SILO:
PS Ratio: 30.43 (60% below median its 10-year median of 75.66)
GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
Industry Position: 220.5% above the Biotechnology median (#684 of 936)
No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score
Get the complete analysis for SILO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SILO has been successfully added to your 
